117 related articles for article (PubMed ID: 37660473)
21. Modelling of organ-specific radiation-induced secondary cancer risks following particle therapy.
Stokkevåg CH; Fukahori M; Nomiya T; Matsufuji N; Engeseth GM; Hysing LB; Ytre-Hauge KS; Rørvik E; Szostak A; Muren LP
Radiother Oncol; 2016 Aug; 120(2):300-6. PubMed ID: 27424291
[TBL] [Abstract][Full Text] [Related]
22. Special radiobiological features of second cancer risk after particle radiotherapy.
Trott KR
Phys Med; 2017 Oct; 42():221-227. PubMed ID: 29103987
[TBL] [Abstract][Full Text] [Related]
23. The risk of induced cancer and ischemic heart disease following low dose lung irradiation for COVID-19: estimation based on a virtual case.
Arruda GV; Weber RRDS; Bruno AC; Pavoni JF
Int J Radiat Biol; 2021; 97(2):120-125. PubMed ID: 33164596
[TBL] [Abstract][Full Text] [Related]
24. The risk of second primary cancers due to peripheral photon and neutron doses received during prostate cancer external beam radiation therapy.
Bezak E; Takam R; Yeoh E; Marcu LG
Phys Med; 2017 Oct; 42():253-258. PubMed ID: 28302493
[TBL] [Abstract][Full Text] [Related]
25. The role of Size-Specific Dose Estimate (SSDE) in patient-specific organ dose and cancer risk estimation in paediatric chest and abdominopelvic CT examinations.
Franck C; Vandevoorde C; Goethals I; Smeets P; Achten E; Verstraete K; Thierens H; Bacher K
Eur Radiol; 2016 Aug; 26(8):2646-55. PubMed ID: 26670320
[TBL] [Abstract][Full Text] [Related]
26. Radiation dose and cancer risk to out-of-field and partially in-field organs from radiotherapy for symptomatic vertebral hemangiomas.
Mazonakis M; Tzedakis A; Lyraraki E; Damilakis J
Med Phys; 2016 Apr; 43(4):1841. PubMed ID: 27036581
[TBL] [Abstract][Full Text] [Related]
27. A comparative study on the risk of second primary cancers in out-of-field organs associated with radiotherapy of localized prostate carcinoma using Monte Carlo-based accelerator and patient models.
Bednarz B; Athar B; Xu XG
Med Phys; 2010 May; 37(5):1987-94. PubMed ID: 20527532
[TBL] [Abstract][Full Text] [Related]
28. Second primary cancers after radiation for prostate cancer: a systematic review of the clinical data and impact of treatment technique.
Murray L; Henry A; Hoskin P; Siebert FA; Venselaar J;
Radiother Oncol; 2014 Feb; 110(2):213-28. PubMed ID: 24485765
[TBL] [Abstract][Full Text] [Related]
29. Introduction of a method to calculate cumulative age- and gender-specific lifetime attributable risk (LAR) of cancer in populations after a large-scale nuclear power plant accident.
Rääf C; Markovic N; Tondel M; Wålinder R; Isaksson M
PLoS One; 2020; 15(2):e0228549. PubMed ID: 32023299
[TBL] [Abstract][Full Text] [Related]
30. The relative risk of second primary cancers in Switzerland: a population-based retrospective cohort study.
Feller A; Matthes KL; Bordoni A; Bouchardy C; Bulliard JL; Herrmann C; Konzelmann I; Maspoli M; Mousavi M; Rohrmann S; Staehelin K; Arndt V;
BMC Cancer; 2020 Jan; 20(1):51. PubMed ID: 31964352
[TBL] [Abstract][Full Text] [Related]
31. Risk of second primary cancer after breast cancer treatment.
Marcu LG; Santos A; Bezak E
Eur J Cancer Care (Engl); 2014 Jan; 23(1):51-64. PubMed ID: 23947545
[TBL] [Abstract][Full Text] [Related]
32. Risk of secondary malignant neoplasms from proton therapy and intensity-modulated x-ray therapy for early-stage prostate cancer.
Fontenot JD; Lee AK; Newhauser WD
Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):616-22. PubMed ID: 19427561
[TBL] [Abstract][Full Text] [Related]
33. Stray radiation dose and second cancer risk for a pediatric patient receiving craniospinal irradiation with proton beams.
Taddei PJ; Mirkovic D; Fontenot JD; Giebeler A; Zheng Y; Kornguth D; Mohan R; Newhauser WD
Phys Med Biol; 2009 Apr; 54(8):2259-75. PubMed ID: 19305045
[TBL] [Abstract][Full Text] [Related]
34. Radiotherapy-induced secondary cancer risk for breast cancer: 3D conformal therapy versus IMRT versus VMAT.
Lee B; Lee S; Sung J; Yoon M
J Radiol Prot; 2014 Jun; 34(2):325-31. PubMed ID: 24705154
[TBL] [Abstract][Full Text] [Related]
35. Secondary cancer risk after whole-breast radiation therapy: field-in-field versus intensity modulated radiation therapy versus volumetric modulated arc therapy.
Haciislamoglu E; Cinar Y; Gurcan F; Canyilmaz E; Gungor G; Yoney A
Br J Radiol; 2019 Oct; 92(1102):20190317. PubMed ID: 31295011
[TBL] [Abstract][Full Text] [Related]
36. Advances in radiotherapy and its impact on second primary cancer risk: A multi-center cohort study in prostate cancer patients.
Jahreiß MC; Hoogeman M; Aben KK; Dirkx M; Snieders R; Pos FJ; Janssen T; Dekker A; Vanneste B; Minken A; Hoekstra C; Smeenk RJ; Incrocci L; Heemsbergen WD
Radiother Oncol; 2023 Jun; 183():109659. PubMed ID: 37003369
[TBL] [Abstract][Full Text] [Related]
37. Secondary cancer risk after radiation therapy for breast cancer with different radiotherapy techniques.
Zhang Q; Liu J; Ao N; Yu H; Peng Y; Ou L; Zhang S
Sci Rep; 2020 Jan; 10(1):1220. PubMed ID: 31988348
[TBL] [Abstract][Full Text] [Related]
38. MONTE CARLO SIMULATION OF OUT-OF-FIELD ORGAN DOSES AND CANCER RISK IN TANZANIA FOR RADIATION THERAPY OF UNILATERAL RETINOBLASTOMA USING A 60Co UNIT.
Suleiman SA; Qi Y; Pi Y; George Xu X
Radiat Prot Dosimetry; 2018 May; 179(3):263-270. PubMed ID: 29216393
[TBL] [Abstract][Full Text] [Related]
39. Out-of-field organ doses and associated radiogenic risks from para-aortic radiotherapy for testicular seminoma.
Mazonakis M; Berris T; Varveris C; Lyraraki E; Damilakis J
Med Phys; 2014 May; 41(5):051702. PubMed ID: 24784368
[TBL] [Abstract][Full Text] [Related]
40. Estimation of Second Primary Cancer Risk After Treatment with Radioactive Iodine for Differentiated Thyroid Carcinoma.
Corrêa NL; de Sá LV; de Mello RC
Thyroid; 2017 Feb; 27(2):261-270. PubMed ID: 27762670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
